824-24-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Methyl-7-azaindole is used as a key intermediate in the synthesis of various drug molecules due to its unique structure and reactivity. Its presence in drug molecules can contribute to their therapeutic effects, making it an essential component in the development of new pharmaceuticals.
Used in Medicinal Chemistry:
4-Methyl-7-azaindole serves as a valuable building block in organic synthesis, facilitating the creation of complex molecular structures with potential medicinal properties. Its versatility in forming different chemical bonds and its compatibility with a range of other compounds make it a preferred choice for researchers in medicinal chemistry.
Used in Drug Discovery:
4-METHYL-7-AZAINDOLE's potential applications in the treatment of various diseases and disorders make 4-Methyl-7-azaindole a promising candidate in drug discovery. Its unique structural features and reactivity can lead to the development of novel therapeutic agents with improved efficacy and selectivity.

InChI:InChI=1/C8H8N2/c1-6-2-4-9-8-7(6)3-5-10-8/h2-5H,1H3,(H,9,10)

Upstream product

• 75-16-1 methylmagnesium bromide 
• 55052-28-3 4-chloro-7-azaindole 

Downstream Products

• 1227270-73-6 4-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 1511867-22-3 4-methyl-5-nitro-1H-pyrrolo[2,3-b]pyridine 

Relevant academic research and scientific papers

PYRROLO [2,3-B]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS

N-(3-Substituted thiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides and N-(3-substituted oxazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamides (I) and (II) are disclosed. The compounds activate Yap and inhibit Lats kinases. They are therefore useful for treating hearing loss.

Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist

The nuclear hormone receptor retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) is a promising target for the treatment of autoimmune diseases. A small molecule, inverse agonist of the receptor is anticipated to reduce production of IL-17, a key proinflammatory cytokine. Through a high-throughput screening approach, we identified a molecule displaying promising binding affinity for RORC2, inhibition of IL-17 production in Th17 cells, and selectivity against the related RORA and RORB receptor isoforms. Lead optimization to improve the potency and metabolic stability of this hit focused on two key design strategies, namely, iterative optimization driven by increasing lipophilic efficiency and structure-guided conformational restriction to achieve optimal ground state energetics and maximize receptor residence time. This approach successfully identified 3-cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide as a potent and selective RORC2 inverse agonist, demonstrating good metabolic stability, oral bioavailability, and the ability to reduce IL-17 levels and skin inflammation in a preclinical in vivo animal model upon oral administration.